Transforming Duchenne muscular dystrophy therapy: The multifaceted role of extracellular vesicles and exosomes.
Farzi F, Soltanmohammadi F, Mohammadi SA, Zarghami N, Alizadeh E
Crispr
Breakthroughs in using nano-scale vesicles to ferry gene-editing cargo into animal cells are reshaping how scientists think about targeted delivery — the same principles are beginning to inform how researchers deliver RNA-based treatments into plant tissues for crop improvement.
Duchenne muscular dystrophy is a serious inherited disease that destroys muscle over time, and current medicines can slow it but not cure it. Scientists are now studying tiny bubbles that cells naturally release to communicate with each other — these bubbles can be loaded with healing genetic instructions and sent directly to damaged muscle. Researchers think these vesicles could one day deliver gene-editing tools precisely enough to actually fix the underlying problem rather than just managing symptoms.
Key Findings
Current DMD treatments including antisense oligonucleotides, CRISPR/Cas9, and cell transplantation can delay but not cure the disease.
Natural extracellular vesicles enriched with regenerative microRNAs and anti-fibrotic proteins can modulate inflammation, oxidative stress, and muscle degeneration.
Engineered exosomes show potential as delivery vehicles for oligonucleotides and CRISPR/Cas9 components to restore dystrophin expression, though challenges in isolation, stability, and scalability remain.
chevron_right Technical Summary
This review examines how tiny cell-secreted particles called extracellular vesicles (especially exosomes) could become new treatment tools for Duchenne muscular dystrophy, a severe muscle-wasting disease. These vesicles can carry gene-editing tools and healing molecules into muscle cells, potentially restoring function where current therapies fall short.
Abstract Preview
Duchenne muscular dystrophy (DMD) remains a devastating X chromosome-linked disorder with restricted curative options. Additionally, the existing treatment approaches, such as growth-modulating age...
open_in_new Read full abstractAbstract copyright held by the original publisher.
Was this useful?
Chloroplast Genome Editing Eliminates Gluten Immunogenicity in Triticum aestivum
It could mean that people with celiac disease — roughly 1 in 100 worldwide — may one day safely eat bread made from real wheat, without sacrificing the taste...